Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening

Platinum resistance is a major cause of treatment failure in ovarian cancer. We previously identified matrix metalloproteinase 9 (MMP-9) as a potential therapeutic target of chemoresistant disease. A2780cis (cisplatin-resistant) and A2780 (cisplatin-sensitive) ovarian carcinoma cell lines were used....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Laios, Alexandros, Mohamed, Bashir M., Kelly, Lynne, Flavin, Richard, Finn, Stephen, McEvoy, Lynda, Gallagher, Michael, Martin, Cara, Sheils, Orla, Ring, Martina, Davies, Anthony, Lawson, Margaret, Gleeson, Noreen, D’Arcy, Tom, d’Adhemar, Charles, Norris, Lucy, Langhe, Ream, Saadeh, Feras Abu, O’Leary, John J., O’Toole, Sharon A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3565367/
https://ncbi.nlm.nih.gov/pubmed/23340649
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms14012085
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi